These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37827135)

  • 1. Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.
    Munker S; Roessler D; Öcal O; Ben-Khaled N; Bernhart K; Ye L; Piseddu I; Vielhauer J; Reiter FP; Rodriguez I; Ricke J; Teufel A; De Toni E; Seidensticker M; Niyazi M; Corradini S
    Oncol Res Treat; 2023; 46(11):466-475. PubMed ID: 37827135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
    Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
    Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
    Chiang CL; Chiu KWH; Chan KSK; Lee FAS; Li JCB; Wan CWS; Dai WC; Lam TC; Chen W; Wong NSM; Cheung ALY; Lee VWY; Lau VWH; El Helali A; Man K; Kong FMS; Lo CM; Chan AC
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):169-178. PubMed ID: 36529152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
    Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
    BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
    Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
    Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
    Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
    Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma.
    Park JH; Yoon SM; Lim YS; Kim SY; Shim JH; Kim KM; Lee HC; Cho B; Park G; Kim JH
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1638-42. PubMed ID: 23621519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
    Lynch C; Korpics MC; Katipally RR; Wu T; Bestvina CM; Pitroda S; Chmura SJ; Juloori A
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1519-1530. PubMed ID: 38199382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.
    Su TS; Liu QH; Zhu XF; Liang P; Liang SX; Lai L; Zhou Y; Huang Y; Cheng T; Li LQ
    Radiat Oncol; 2021 Apr; 16(1):79. PubMed ID: 33882972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma.
    Park S; Yoon WS; Jang MH; Rim CH
    Int J Radiat Biol; 2020 Dec; 96(12):1541-1549. PubMed ID: 32990486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
    Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
    Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.